Cobalt(II) chloride (CoCl2)

Cobalt(II) chloride is an inorganic chemical compound that acts as a potent hypoxia mimetic, rather than being a biological therapeutic target itself (PubChem CID 24872). It is widely used in research to simulate low-oxygen conditions by stabilizing hypoxia-inducible factor 1-alpha (HIF-1α), a master transcriptional regulator of the adaptive response to hypoxia (Yuan et al., 2003). The compound exerts this effect by inhibiting prolyl hydroxylase domain (PHD) enzymes, which normally mark HIF-1α for degradation; cobalt ions achieve this by competing with the essential iron (Fe2+) cofactor in the enzyme's catalytic site (Munoz-Sanchez & Chanez-Cardenas, 2018). Historically, cobalt chloride was administered to treat various forms of anemia because it stimulates the endogenous production of erythropoietin (EPO), though this practice has been largely discontinued due to significant toxicity (StatPearls, 2023). Clinical use is restricted by a narrow therapeutic index and risks of severe adverse effects, including cardiomyopathy, thyroid dysfunction, and polycythemia (IARC, 2006). Furthermore, cobalt(II) chloride is classified as a probable human carcinogen, limiting its application primarily to laboratory settings for studying angiogenesis, cellular metabolism, and ischemic injury (IARC, 2023).

Other names

Cobaltous chlorideCobalt dichlorideCobalt(2+) chloride

Cobalt(II) chloride acts as a hypoxia mimetic by inhibiting prolyl hydroxylase domain (PHD) enzymes. It competes with the essential Fe(II) cofactor in the enzyme's active site, preventing the oxygen-dependent hydroxylation of HIF-1α. This stabilization allows HIF-1α to translocate to the nucleus, dimerize with HIF-1β, and activate the transcription of genes such as erythropoietin (EPO) and vascular endothelial growth factor (VEGF) (Yuan et al., 2003; Munoz-Sanchez & Chanez-Cardenas, 2018).